Agenus Q2 revenue $34.5M; $85M placement funds Phase 3 ROBBIN trial in MSS colon cancer

AGENUS INC

Q2 total revenue $34.5M (up from $25.7M YoY); pre-commercial product revenue $6.4M.
Completed $85M private placement in July; warrants could add up to $255M.
Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer to start Q1 2027; targets 38,000 US patients annually.
Discontinued funding for BATTMAN Phase 3 study (CCTG sponsored) to prioritize ROBBIN.
Near-term milestones: NEST/UNICORN manuscripts H2 2026; corporate webcast Sept 10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.